Human CCR4 deadenylase homolog Angel1 is a non-stop mRNA decay factor
- Tim Nicholson-Shaw1,
- Megan E. Dowdle1,
- Yasmeen Ajaj1,
- Mark Perelis2,3,4,
- Amit Fulzele1,
- Gene W. Yeo2,3,4,
- Eric J. Bennett1 and
- Jens Lykke-Andersen1
- 1Division of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA
- 2Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California 92093, USA
- 3Stem Cell Program, University of California San Diego, Sanford Consortium for Regenerative Medicine, La Jolla, California 92037, USA
- 4Institute for Genomic Medicine, University of California San Diego, La Jolla, California 92093, USA
- Corresponding author: jlykkeandersen{at}ucsd.edu
-
Handling editor: Javier Caceres
Abstract
Translation elongation stalls trigger mRNA decay and degradation of the nascent polypeptide via translation-dependent quality control pathways. One such pathway, non-stop mRNA decay (NSD), targets aberrant mRNAs that lack stop codons, for example, due to premature polyadenylation. Here we identify Angel1, a CCR4 deadenylase homolog whose biochemical activity remains poorly defined, as a rate-limiting factor for NSD in human cells. Angel1 associates with mRNA coding regions and proteins involved in ribosome-associated quality control and mRNA decay, consistent with a factor that monitors translation elongation stalls. Depletion of Angel1 causes stabilization of reporter mRNAs that are targeted for NSD by the absence of stop codons, but not an mRNA targeted for nonsense-mediated decay. A conserved catalytic residue of Angel1 is critical for its function in NSD. Our findings identify Angel1 as a human NSD factor and suggest that Angel1 catalytic activity plays a critical role in the NSD pathway.
Keywords
Footnotes
-
Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna.080399.125.
-
Freely available online through the RNA Open Access option.
- Received January 28, 2025.
- Accepted May 2, 2025.
This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.










